Loading…
AnaptysBio, Inc. is projected to rise to $82.70 by 2027, a +55% move from its current price of $53.36. ANAB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $51.12 | $53.36 | $55.70 | 0.00% |
| Aug 3 | $50.22 | $53.36 | $56.71 | +0.01% |
| Aug 4 | $49.54 | $53.37 | $57.49 | +0.01% |
| Aug 5 | $48.97 | $53.37 | $58.16 | +0.01% |
| Aug 6 | $48.48 | $53.37 | $58.75 | +0.02% |
| Aug 7 | $48.04 | $53.37 | $59.29 | +0.02% |
| Aug 8 | $47.64 | $53.37 | $59.80 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $47.64 | $53.37 | $59.80 | +0.02% |
| Week 2 | $45.46 | $53.38 | $62.70 | +0.05% |
| Week 3 | $43.85 | $53.40 | $65.02 | +0.07% |
| Week 4 | $42.55 | $53.41 | $67.05 | +0.09% |
| Week 5 | $41.43 | $53.42 | $68.89 | +0.12% |
| Week 6 | $40.45 | $53.44 | $70.59 | +0.14% |
| Week 7 | $39.56 | $53.45 | $72.20 | +0.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AnaptysBio, Inc. is a healthcare company focused on immunology therapeutics for autoimmune and inflammatory diseases in the United States. It develops antibody programs across preclinical and clinical stages and pursues collaborations with other industry players to advance its portfolio.
The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody in a Phase 1a trial targeting plasmacytoid dendritic cells and interferon signaling; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor and is in Phase 3 development for generalized pustular psoriasis. It highlights collaborations with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc.
and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
AnaptysBio, Inc. (ANAB) trades as a healthcare stock with a current price of $54.91 and a market cap of $1.63B. It is ranked 2139 by market capitalization and operates in the healthcare sector, focusing on immunology therapies in autoimmune and inflammatory diseases.
The stock’s near-term price pattern shows a bullish tilt on sentiment, while the longer-term forecast envisions substantial upside across multiple years. The 30-day technical picture sets a framework for short-term price action in a volatile environment.
A major floor 30.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.8% below — buyers have tended to step in here.
The nearest ceiling, 30.8% above — a clean break opens room to run.
A major ceiling 44.9% above — clearing it would confirm fresh momentum.
Key ANAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $53.25 | Buy | $53.59 | Sell |
| MA 10 | $53.20 | Buy | $54.41 | Sell |
| MA 20 | $58.01 | Sell | $56.23 | Sell |
| MA 50 | $57.72 | Sell | $56.97 | Sell |
| MA 100 | $54.55 | Sell | $53.14 | Buy |
| MA 200 | $42.25 | Buy | $44.63 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.04 | Neutral |
| Stoch RSI (14) | 50.02 | Neutral |
| CCI (20) | -57.21 | Neutral |
| Williams %R (14) | -74.88 | Info |
| MACD (12,26,9) | -0.51 | Sell |
| ROC (12) | -4.41 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 25.12 | Neutral |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -5.89 | Sell |
| Ultimate (7,14,28) | 45.87 | Neutral |
| Momentum (10) | -4.64 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 53.25 | Buy |
| ADX (14) | 16.88 | Neutral |
| ATR (14) | 2.27 | Info |
The near-term technical picture is bullish in sentiment. The RSI(14) sits at 40, with the 50-day simple moving average at $58.76 and the 200-day simple moving average at $41.27, suggesting that the stock has room to move higher should momentum improve. Support is identified at $50.29 and resistance at $69.81, indicating a potential trading range around the current area.
The stock has traded in a 30-day range from $39.77 to $75.82, reflecting notable volatility as implied by an annualized volatility of 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.80 | $53.36 | $73.28 | 0% | Neutral | |
| $62.51 | $82.70 | $117.49 | +55% | Bullish | |
| $71.89 | $99.71 | $149.62 | +87% | Bullish | |
| $70.04 | $101.09 | $158.20 | +89% | Bullish | |
| $79.76 | $119.29 | $193.29 | +124% | Bullish | |
| $86.88 | $134.29 | $224.23 | +152% | Bullish | |
| $98.99 | $157.82 | $270.65 | +196% | Bullish | |
| $128.99 | $211.80 | $372.03 | +297% | Bullish | |
| $149.86 | $253.14 | $454.50 | +374% | Bullish | |
| $167.46 | $290.74 | $532.66 | +445% | Bullish | |
| $253.78 | $501.37 | $998.53 | +840% | Bullish | |
| $423.06 | $940.13 | $2,107.96 | +16.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $28.80 | $53.36 | $64.63 | +0.00% |
| September 2026 | $42.56 | $51.22 | $63.99 | -4.01% |
| October 2026 | $44.00 | $53.52 | $67.96 | +4.49% |
| November 2026 | $45.85 | $56.28 | $72.39 | +5.14% |
| December 2026 | $45.49 | $56.30 | $73.28 | +0.04% |
Click any year to see its month-by-month ANAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ANAB price prediction for 2026 points to an average of $53.36 (low $28.80, high $73.28) — a potential gain of 0% on today's $53.36. A consolidation phase looks the most probable path here.
In 2027, ANAB is projected to trade between $62.51 and $117.49, averaging $82.70 — a potential gain of +55% from today's $53.36. That is up +55% on the projected 2026 average. Momentum favours further upside here.
AnaptysBio, Inc.'s 2028 outlook centres on $99.71, within a $71.89 to $149.62 range. That is up +21% on the projected 2027 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ANAB could reach as high as $158.20, with a base case around $101.09 and support toward $70.04 — roughly +89% from $53.36. Momentum favours further upside here.
Expect ANAB to range from $79.76 to $193.29 through 2030. The $119.29 average target implies a +124% move from current prices. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ANAB price prediction for 2031 points to an average of $134.29 (low $86.88, high $224.23) — a potential gain of +152% on today's $53.36. Momentum favours further upside here.
In 2032, ANAB is projected to trade between $98.99 and $270.65, averaging $157.82 — a potential gain of +196% from today's $53.36. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
AnaptysBio, Inc.'s 2033 outlook centres on $211.80, within a $128.99 to $372.03 range. That is up +34% on the projected 2032 average. That marks a +297% change versus current levels. Momentum favours further upside here.
By 2034, ANAB could reach as high as $454.50, with a base case around $253.14 and support toward $149.86 — roughly +374% from $53.36. Buyers look set to stay in control over this stretch.
Expect ANAB to range from $167.46 to $532.66 through 2035. The $290.74 average target implies a +445% move from current prices. That is up +15% on the projected 2034 average. Momentum favours further upside here.
The ANAB price prediction for 2040 points to an average of $501.37 (low $253.78, high $998.53) — a potential gain of +840% on today's $53.36. Buyers look set to stay in control over this stretch.
In 2050, ANAB is projected to trade between $423.06 and $2,107.96, averaging $940.13 — a potential gain of +16.6x from today's $53.36. That is up +88% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ANAB today (≈ 18.74063 ANAB) could be worth
$17,618.69
+$16,618.69 (+1662%) by 2050 · US Dollar
Based on the average projected ANAB price of $940.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANABwould be worth at today's price.
$1,000 invested in ANAB on Jul 31, 2025 (≈ 61.099796 ANAB) would be worth
$3,260.29
+$2,260.29 (+226.0%) today · 3.26× · US Dollar
Based on a ANAB entry price of $16.37 vs. today's $53.36.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $54.15 | $985.41 | -1.5% |
| 1 month ago | $65.43 | $815.53 | -18.4% |
| 3 months ago | $66.76 | $799.28 | -20.1% |
| 6 months ago | $33.69 | $1,583.7 | +58.4% |
| 1 year ago | $16.37 | $3,260.29 | +226.0% |
| All time (5.0y) ago | $15.67 | $3,404.51 | +240.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANAB forecast.
Our base-case forecast reaches $110.00 around 2030.
Implied market cap at $110.00: $3.26B
The year-by-year forecast shows meaningful upside beyond the near term. In 2030 the average price is projected at $125.83 with a max of $212.10 and a min of $80.53, delivering an implied ROI of 129.2% and a bullish sentiment for the period. Earlier years trend steadily higher, with 2027 avg $88.21 and 2028 avg $104.80 (ROI 60.6% and 90.9% respectively), and continuing into 2031–2035 with multi-hundred-dollar-average targets and strong upside (2033 avg $230.04, ROI 318.9%; 2034 avg $272.04, ROI 395.4%; 2035 avg $309.58, ROI 463.8%).
The long-range view extends to 2040, where the avg is $541.57 (ROI 886.3%), and to 2050, with an avg of $996.34 (ROI 1714.5%). The forecast shows bullish sentiment in those later years, underscoring substantial upside potential while acknowledging the inherent uncertainty of forward estimates. The 30-day range and volatility data highlight ongoing price volatility that investors should consider when weighing the long horizon.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $125.83 with a min of $80.53 and a max of $212.10, and an implied ROI of 129.2%, with bullish sentiment in that year.
Forecasts indicate bullish sentiment from 2027 onward, with rising average prices: 2027 avg $88.21, 2028 avg $104.80, 2029 avg $102.64, 2030 avg $125.83, 2031 avg $139.32, 2032 avg $161.84, 2033 avg $230.04, 2034 avg $272.04, 2035 avg $309.58, 2040 avg $541.57, and 2050 avg $996.34. These are estimates and not guarantees.
Yes. The 2030 forecast lists a max of $212.10, with a min of $80.53 and an avg of $125.83 (ROI 129.2%, bullish).
The forecast shows a max of $1,141.67 in 2040 and $2,291.59 in 2050, with respective avg prices of $541.57 and $996.34 and ROIs of 886.3% and 1714.5%, both bullish in those years.
AnaptysBio, Inc. Community Discussion
0Share your AnaptysBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.